Simulations Plus announced that the U.S. FDA has renewed its licenses to the DILIsym software platform. DILIsym is the industry gold standard for quantitative systems toxicology, QST, software designed for the prediction and investigation of drug-induced liver injury, DILI. The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Simulations Plus Q2 Financial Performance and Outlook Warning
- Options Volatility and Implied Earnings Moves Today, April 03, 2024
- Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
- Simulations Plus (SLP) Q2 Earnings Cheat Sheet
- FDA awards Simulations Plus a grant through proposal with University of Bath